| Literature DB >> 33628200 |
Irene Gagliardi1, Mario Tarquini1, Maria Rosaria Ambrosio1,2, Elisa Giannetta3, Patricia Borges de Souza1, Roberta Gafà4, Aldo Carnevale5, Paola Franceschetti2, Maria Chiara Zatelli1,2.
Abstract
Survival prognostic markers are extremely needed to better define therapeutic strategies in patients with bronchial carcinoids (BC). We aim to verify the applicability of the NEP-Score in a homogeneous BC cohort and identify a derivative prognostic marker, the NEP-Score at diagnosis (NEP-D) that does not consider new metastases during follow-up. Sixty-four patients (38 females, and 26 males, mean age at diagnosis 58.9 ± 1.7 years) with BC were retrospectively evaluated. NEP-Score was calculated at the end of follow-up (NEP-T). A derivative score, the NEP-Score at diagnosis (NEP-D) that does not consider new metastases during follow-up, was then assessed. Patients were subdivided according to their living status at the end of follow-up. A NEP-Score threshold was investigated to predict survival. Mean NEP-T and mean NEP-D were significantly lower in live patients at end of follow-up. A NEP-T cut-off >138 significantly predicts survival. Atypical BC relapsed more frequently than Typical BC. Male gender and previous malignancy were negative prognostic factors for survival. We confirmed NEP-Score applicability in BC and NEP-D utility, being the latter a simple, quick, and cheap prognostic score that can help clinicians in decision making. The identified NEP-D threshold can predict NEN aggressiveness and may be used to define the best personalized therapeutic strategy. In this context, a validation study is needed.Entities:
Keywords: Delta NEP score; NEP-D; NEP-Score; NEP-T; bronchial neuroendocrine neoplasms; survival
Mesh:
Year: 2021 PMID: 33628200 PMCID: PMC7897663 DOI: 10.3389/fendo.2020.621557
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 5.555